Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-2 Immunotoxin and Peptide Vaccination in Metastatic Melanoma
NCT00295958Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Dec 2005
- Primary completion
- Jun 2006
- Modality
- Immunotoxins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LMB-2 in melanoma, sponsored by National Institutes of Health. Primary endpoint: Objective Clinical Response Rate. Started Dec 2005; status: completed.
02
Drugs
LMB-2
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00295958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295958.